Dover, DE and Sydney, Australia, Nov. 12, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (Nasdaq: ATON) and its wholly owned oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado ...
Australia has one of the world's highest measured rates of mesothelioma — an asbestos-related cancer — with more than 700 people here dying from the disease each year. Could a non-invasive PCR test — ...
“ADDRI’s leadership in asbestos-related disease makes Australia a compelling setting for a TT-4 investigator-initiated trial,” said Peter Molloy, Chief Executive Officer, Cyncado Therapeutics. “We are ...
ADDRI-sponsored trial in Australia planned to enroll approximately 50 patients, led by A/Prof Steven Kao and Dr Melvin Chin; part of Cyncado’s international program for mesothelioma ADDRI-sponsored ...
(MENAFN- GlobeNewsWire - Nasdaq) ADDRI-sponsored trial in Australia planned to enroll approximately 50 patients, led by A/Prof Steven Kao and Dr Melvin Chin; part of Cyncado's international program ...
ADDRI to sponsor an investigator-initiated clinical trial of TT-4 in mesothelioma in Australia (planned enrollment of 50 patients) Addresses the urgent need after first-line therapy, where there is no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results